… Finally, the EPHESUS trial [14], the first major trial of eplerenone in post-myocardial infarction
HFrEF, demonstrated that the addition of eplerenone to optimal medical therapy reduced …

… in post-myocardial infarction (MI) and heart failure (HF… infarct size reduction with treatment
could be due to different species, ischemic procedure and techniques used to calculate infarct …

… patients with nonischemic dilated cardiomyopathy or ischemic heart disease at least 40 days
post-myocardial infarction … or patients at least 40 days post-myocardial infarction with LVEF …

… Lower starting doses were used for patients with low systolic blood … treatment with
sacubitril/valsartan vs valsartan in a post–myocardial infarction population did not alter cardiac …

… (sacubitril/valsartan) can lower the risk of cardiovascular events in chronic heart failure. …
patients with acute myocardial infarction (MI). The present study shows that LCZ696 can prevent …

… use of sacubitril/valsartan (Entresto ® ), the newly FDA-approved medication that dually inhibits
angiotensin and neprilysin, in the treatment of heart failure… the post-myocardial infarction …

… treatment of heart failure and post-myocardial infarction (MI). In a randomized, double-blind,
placebo-controlled investigation called Val-HeFT, valsartan treatment … the usage of valsartan …

… (MI), the prevalence of post-MI heart failure continues to rise. … patients found no differences
in efficacy between valsartan … % with the use of the MRA eplerenone in post-MI patients with a …

… Patients with post-myocardial infarction HF were older, more likely to be women, to … use of
percutaneous coronary intervention, the percentage of patients with post-infarction ventricular …

… of carperitide is used as a treatment for acute decompensated heart failure in Japan without
… Von Lueder et al. randomized post-myocardial infarction adult male Sprague-Dawley rats to …